Top Page
Biome Australia Ltd
(Sydney:BIO)
Biome Australia Ltd (BIO) vs. iShares MSCI Australia ETF (EWA)
Biome Australia Ltd Business Overview & Revenue Model
Biome Australia Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.42M | 18.42M | 13.01M | 7.24M | 4.11M | 2.32M |
| Gross Profit | 11.26M | 11.26M | 7.91M | 4.06M | 2.38M | 1.07M |
| EBITDA | 143.57K | 143.57K | -1.58M | -3.15M | -4.65M | -5.39M |
| Net Income | 214.66K | 214.66K | -1.67M | -3.08M | -4.54M | -5.38M |
Balance Sheet | ||||||
| Total Assets | 11.97M | 11.97M | 8.28M | 7.56M | 8.25M | 11.09M |
| Cash, Cash Equivalents and Short-Term Investments | 2.75M | 2.75M | 2.87M | 2.26M | 5.49M | 634.61K |
| Total Debt | 3.07M | 3.07M | 1.30M | 1.15M | 467.05K | 81.00K |
| Total Liabilities | 7.29M | 7.29M | 5.37M | 3.97M | 1.73M | 920.00K |
| Stockholders Equity | 4.68M | 4.68M | 2.90M | 3.59M | 6.53M | 10.17M |
Cash Flow | ||||||
| Free Cash Flow | -2.86M | -2.86M | -185.41K | -3.90M | -3.55M | -2.46M |
| Operating Cash Flow | -2.82M | -2.82M | -163.81K | -3.50M | -3.42M | -2.39M |
| Investing Cash Flow | -200.38K | -200.38K | -21.61K | -400.94K | -99.34K | -28.77K |
| Financing Cash Flow | 2.90M | 2.90M | 793.17K | 665.21K | 8.40M | 2.58M |
Biome Australia Ltd Technical Analysis
Biome Australia Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
51 Neutral | ― | 465.00 | 5.66% | ― | 41.57% | ― | |
46 Neutral | AU$22.04M | ― | -143.71% | ― | 306.88% | ― | |
42 Neutral | AU$8.54M | -2.30 | ― | ― | ― | ― | |
40 Underperform | AU$2.17M | -4.33 | -28.49% | ― | ― | 46.43% | |
37 Underperform | AU$5.68M | ― | -628.72% | ― | ― | 31.87% | |
27 Underperform | AU$3.21M | ― | -205.70% | ― | ― | 1.03% |
Biome Australia Ltd Corporate Events
Biome Australia Ltd has announced a virtual-only shareholder meeting scheduled for November 26, 2025. Shareholders are encouraged to vote online or via proxy forms, with instructions provided for electronic communication preferences. The company emphasizes the importance of reviewing the Notice of Meeting and submitting questions in advance to facilitate management’s preparation.
The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has reported a record quarterly sales revenue of $5.94 million for the first quarter of FY26, marking a 40% increase compared to the previous corresponding period and a 19% rise quarter-on-quarter. This achievement represents the company’s seventh consecutive quarter of positive EBITDA, amounting to $462,000, and highlights its strong financial performance with a cash balance increase to $2.94 million, indicating robust operational cash flow and financial stability.
The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has announced a Quarterly Results webinar scheduled for October 23, 2025, where the company’s Managing Director, Blair Vega Norfolk, will provide an update on the company’s quarterly performance. This event is an opportunity for investors to engage with the company and gain insights into its operations and market positioning, potentially impacting stakeholder perspectives and investment decisions.
The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited reported record quarterly sales revenue of $5.94 million for Q1 FY26, surpassing its forecast by 8% and marking a 40% increase from the previous year. This growth highlights Biome’s strong market position and product demand, positioning the company on track to achieve its Vision 27 revenue guidance of at least $75 million.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement, approved by the board, outlines the company’s adherence to the ASX Corporate Governance Council’s recommendations, providing transparency and accountability to stakeholders.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has announced that its Annual General Meeting (AGM) will be held on 26 November 2025, with the closing date for director nominations set for 8 October 2025. This announcement is part of the company’s compliance with ASX Listing Rules and its Constitution. The AGM will provide shareholders with further details in a separate Notice of Meeting. This meeting is a significant event for stakeholders as it will address company governance and future strategic directions.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has announced that its Q1 FY26 sales revenue is expected to exceed $5.5 million, setting a new quarterly revenue record and surpassing the previous record of $5.0 million achieved in Q4 FY25. This growth reflects the company’s strong market position and the increasing demand for its innovative probiotic products, potentially enhancing its industry standing and offering positive implications for stakeholders.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has announced a strategic partnership with Green Cross Health, New Zealand’s leading integrated healthcare provider. This collaboration allows Biome’s Activated Probiotics to be launched across New Zealand’s largest pharmacy network, comprising 328 stores under the Life Pharmacy and UniChem brands. The partnership is a significant step in Biome’s international expansion strategy, leveraging Green Cross Health’s extensive retail market penetration and Propharma’s wholesale distribution infrastructure. With New Zealand’s natural health products market growing and pharmacies capturing the majority of sales, this move positions Biome favorably in the market.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Ltd has announced strategic distribution agreements with Mecca, a leading premium beauty retailer, and Go Vita, Australia’s largest health food network, to expand the reach of its Activated Probiotics range. The partnership with Mecca marks Biome’s entry into the premium beauty retail sector, providing exposure to a new audience through Mecca’s flagship store in Melbourne, which features a dedicated wellness hub. Meanwhile, the agreement with Go Vita allows Biome to leverage Australia’s largest health food distribution platform, aligning with their strategy to diversify distribution channels while maintaining a practitioner-recommended model. These partnerships are expected to accelerate Biome’s growth trajectory and validate the increasing convergence of beauty and wellness, highlighting the importance of gut health in overall wellbeing.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited reported a breakthrough financial year in 2025, achieving its first net profit of $214,656 and a 41.6% increase in sales revenue to $18.4 million. The company saw substantial growth across all key metrics, with international sales rising by 69% and strategic partnerships established in Canada, Ireland, the UK, and New Zealand. Biome’s Activated Probiotics brand became the second-largest in probiotic revenue within community pharmacies, and the company is on track to meet its Vision 27 forecast of $75 million in cumulative sales for FY25-27.
The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Ltd has announced that Raymond Demaio Pty Ltd ATF Raymond Demaio Family Trust has ceased to be a substantial holder in the company as of July 31, 2025. This change occurred due to an off-market transfer of 2,300,000 fully paid ordinary shares to HSBC Australia as security for a master loan agreement, impacting the voting rights and shareholding structure of Biome Australia Ltd.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.